Table 3.
Association between characteristics of articles and statistically significant outcome or conclusions that favor the test drug: Multivariate logistic regression (full sample, n = 137)
| Results Favor Test Drug | Conclusions Favor Test Drug | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic | Category | Favorable n/Total n (%) |
OR (95% CI) |
P | Favorable n/Total n (%) |
OR (95% CI) |
P |
| Trial registration before publication | No | 44/83 (53) | 1.00 | 55/83 (66) | 1.00 | ||
| Yes | 36/54 (67) | 1.29 (0.54-3.08) | 0.566 | 43/54 (80) | 1.56 (0.60-4.05) | 0.363 | |
| Blinding | Stringent | 18/36 (50) | 1.00 | 25/36 (69) | 1.00 | ||
| Not stringent | 62/101 (61) | 2.33 (0.95-5.76) | 0.066 | 73/101 (72) | 1.51 (0.59-3.91) | 0.394 | |
| Sample Size | Natural log | - | 2.28 (0.87-4.90) | <0.001 | - | 1.77 (1.18-2.66) | 0.006 |
| Comparison group | Active comparator | 35/65 (54) | 1.00 | 45/65 (69) | 1.00 | ||
| Placebo | 45/72 (63) | 2.06 (0.87-4.90) | 0.101 | 53/72 (74) | 1.47 (0.59-3.63) | 0.410 | |
| Primary efficacy outcome | Survival | 17/30 (57) | 1.00 | 21/30 (70) | 1.00 | ||
| Surrogate | 63/107 (59) | 3.42 (1.15-10.14) | 0.027 | 77/107 (72) | 3.04 (0.95-9.68) | 0.061 | |
| Sponsored | No | 14/28 (50) | 1.00 | 15/28 (54) | 1.00 | ||
| Yes | 66/109 (61) | 1.01 (0.37-2.67) | 0.999 | 83/109 (76) | 2.01 (0.76-5.31) | 0.157 | |